On Friday, CytomX Therapeutics Inc (NASDAQ: CTMX) was 7.31% up from the session before settling in for the closing price of $2.19. A 52-week range for CTMX has been $0.40 – $3.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -125.89%. With a float of $130.57 million, this company’s outstanding shares have now reached $157.54 million.
Let’s determine the extent of company efficiency that accounts for 121 employees. In terms of profitability, gross margin is 64.9%, operating margin of 24.37%, and the pretax margin is 28.35%.
CytomX Therapeutics Inc (CTMX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward CytomX Therapeutics Inc stocks. The insider ownership of CytomX Therapeutics Inc is 34.47%, while institutional ownership is 34.24%. The most recent insider transaction that took place on Jun 16 ’25, was worth 28,540. In this transaction Chief Financial Officer of this company sold 10,614 shares at a rate of $2.69, taking the stock ownership to the 226,271 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Chief Financial Officer sold 1,641 for $2.95, making the entire transaction worth $4,841. This insider now owns 199,385 shares in total.
CytomX Therapeutics Inc (CTMX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -125.89% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
You can see what CytomX Therapeutics Inc (CTMX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.50, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Looking closely at CytomX Therapeutics Inc (NASDAQ: CTMX), its last 5-days average volume was 1.66 million, which is a drop from its year-to-date volume of 3.17 million. As of the previous 9 days, the stock’s Stochastic %D was 35.17%.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 72.36%, which indicates a significant increase from 53.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.13 in the past 14 days, which was lower than the 0.16 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.41, while its 200-day Moving Average is $1.30. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $2.44. Second resistance stands at $2.53. The third major resistance level sits at $2.66. If the price goes on to break the first support level at $2.22, it is likely to go to the next support level at $2.09. Should the price break the second support level, the third support level stands at $2.00.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are 80,621K outstanding shares of the company, which has a market capitalization of 370.23 million. As of now, sales total 138,100 K while income totals 31,870 K. Its latest quarter income was 50,920 K while its last quarter net income were 23,530 K.
